Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

09/08/2011 | 10:10pm US/Eastern

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

React to this article
Latest news on ASTELLAS PHARMA INC
09/02 ASTELLAS PHARMA : Recent Research from Astellas Pharma, Inc. Highlight Findings ..
08/27 ASTELLAS PHARMA : Studies from Astellas Pharma, Inc. in the Area of Pain Describ..
08/27 ASTELLAS PHARMA : Study Results from Astellas Pharma, Inc. Broaden Understanding..
08/27 ASTELLAS PHARMA : New Medicinal Chemistry Findings from Astellas Pharma, Inc. Re..
08/27 ASTELLAS PHARMA : Researchers from Astellas Pharma, Inc. Report Findings in Card..
08/27 ASTELLAS PHARMA : Details Findings in Pain (Discovery of an 8-methoxytetrahydroi..
08/27 ASTELLAS PHARMA : Notice of Completion of Acquisition of Own Shares (Under the p..
08/26 ASTELLAS PHARMA : Notice of Completion of Acquisition of Own Shares (pdf 41KB)
08/20 ASTELLAS PHARMA : Announces Changes in Personnel and Sales and Marketing Structu..
08/18 ASTELLAS PHARMA : Basilea reports 2015 half-year results - Major milestones achi..
Advertisement
Chart
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Income Statement Evolution
More Financials